# R-Pharm

R-Pharm is a Corporate Investor based in Moscow, Russia.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Moscow, Russia
- **Region:** Europe
- **Address:** Moscow, Russia
- **Founded:** 2001
- **Assets under management:** Undisclosed
- **Website:** r-pharm.com
- **LinkedIn:** https://www.linkedin.com/company/r-pharm
- **Wikidata:** Q18398598

## Regulatory record

- **Reports private funds:** No

## About

R-Pharm is a privately held pharmaceutical company founded by Alexey Repik in 2001 and headquartered in Moscow. Repik entered the industry after early work in medical equipment distribution, scaling the firm into one of Russia's largest pharma enterprises by revenue without a public listing. The wealth origin is wholly operational — Repik retains full control and has not separated investment activity into a standalone family office. The firm deploys capital through direct corporate investment rather than external fund commitments. Manufacturing infrastructure absorbs the heaviest expenditures: a production plant in Illertissen, Bavaria, and a second in St. Petersburg produce sterile injectables, oncology drugs, and biosimilars. Licensing partnerships with global pharma majors — most notably AstraZeneca, which contracted R-Pharm to produce the adenovirus-based COVID-19 vaccine in Russia — generate recurring revenue streams. In 2017, Japanese trading house Mitsui & Co. acquired a 10% stake for $200 million, valuing the firm at $2 billion and signaling institutional appetite for its ex-Russia manufacturing footprint. The firm also holds real estate assets including a San Francisco residential property and a Moscow-area logistics lease. The operating team remains lean at the top. Alexey Repik runs the group as founder and primary decision-maker. His mother Valeria Daeva appears as owner of affiliated entity Petrusko and holds a shareholder position. Repik sits on the Russian Union of Industrialists and Entrepreneurs general council and chairs the Business Russia professional network, roles that embed R-Pharm within industrial-policy circles. No dedicated investment team, separate family office vehicle, or third-party capital is publicly disclosed. May 2022: Repik stepped down as chairman of the board while retaining ownership control, a governance move reported by Russian business media. R-Pharm is structurally distinct from any allocator archetype. It functions as an operating company — not a family office, not a fund — that generates and reinvests industrial cashflows. There is no external LP capital, no fund vehicles, and no co-investment club. The political adjacency is material: Repik has been publicly linked to Katerina Tikhonova, the daughter of Vladimir Putin, and RDIF has provided co-investment for select projects. Any institutional co-investor evaluating exposure to Russian pharma manufacturing must weigh this proximity against the firm's genuine operational scale.

## Sectors

- Pharmaceuticals
- Healthcare Services
- Real Estate
- Manufacturing

## Offices

- Illertissen, Germany
- St. Petersburg, Russia

## People

- Alexey Repik — Founder

## Questions

### Who runs investment decisions at R-Pharm?

Alexey Repik, the founder and primary owner, makes all material capital-allocation decisions. The firm has no dedicated investment committee, no external investment staff disclosed, and no separate family office. Strategic moves — including the Mitsui minority sale and manufacturing-plant builds — are routed through the corporate entity under Repik's direction.

### What is R-Pharm's geographic footprint?

The firm operates manufacturing in Germany and Russia, with distribution and licensing partnerships spanning the US, Japan, Turkey, the Middle East, and North Africa. Real estate holdings include a San Francisco residential property and a Moscow-area logistics lease. No office roster beyond the manufacturing sites is disclosed.

## Related profiles

- [RPG Ventures](https://altss.com/profile/rpg-ventures)
- [RPM Advisors](https://altss.com/profile/rpm-advisors)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/r-pharm

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology